Lingrui Pharma(600285) 东北证券·2024-08-13 08:00Investment Rating - The investment rating for the company is "Buy" [1][5] Core Insights - The company reported a revenue of 1.906 billion yuan for the first half of 2024, representing a year-over-year increase of 12.07%. The net profit attributable to shareholders was 413 million yuan, up 30.3% year-over-year [2][3] - The company has shown improvements in sales efficiency and the effectiveness of its digital transformation, with a significant reduction in expense ratios and an increase in profit margins [3] - The multi-brand strategy has led to sustained growth in brand value, with the company expanding its brand portfolio and enhancing its market presence [3] Financial Summary - For 2024, the company is projected to achieve revenues of 3.79 billion yuan, with a year-over-year growth rate of 14.45%. The net profit attributable to shareholders is expected to be 707 million yuan, reflecting a growth rate of 24.42% [4][5] - The earnings per share (EPS) for 2024 is estimated at 1.25 yuan, with a price-to-earnings (P/E) ratio of 18.49 [4][5] - The company’s gross margin is projected to be 74.3% in 2024, with a net profit margin of 18.7% [7]